| Characteristics | Recent users | Remote users | p-value |
| N | 25 | 23 | – |
| Male | 22 (88%) | 19 (83%) | 0.70 |
| Age (years) | 49.6 ± 6.9 | 51.4 ± 6.3 | 0.35 |
| Education (years) | 13.9 ± 2.2 | 14.6 ± 2.3 | 0.27 |
| Caucasian race | 17 (68%) | 10 (44%) | 0.15 |
| Years since HIV diagnosis | 13.1± 6.4 | 13.7 ± 7.4 | 0.79 |
| Years on combination antiretroviral therapy | 11.0 ± 5.5 | 11.2 ± 6.7 | 0.92 |
| Nadir CD4 count (cells/mm3), median (Q1 - Q3) | 175 (10 - 250) | 85.0 (50 - 245) | 0.71‡ |
| Current CD4 count (cells/mm3), median (Q1 - Q3) | 466 (281 - 641) | 439 (325 - 592) | 0.98‡ |
| Undetectable plasma HIV RNA (<50 copies/mL) | 22 (88%) | 18 (78%) | 0.45 |
| Cannabis use | |||
| Lifetime frequency of use (0 - 10 times) | 1 (4%) | 8 (35%) | 0.01 |
| Lifetime frequency of use (>10 times) | 24 (96%) | 15 (65%) | 0.01 |
| Duration of cannabis use (years) | 25 (5 - 30) | 8 (3 - 18) | 0.01‡ |